Comparative Pharmacology
Head-to-head clinical analysis: HADLIMA versus SIMLANDI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HADLIMA versus SIMLANDI.
HADLIMA vs SIMLANDI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adalimumab is a recombinant human IgG1 monoclonal antibody that binds specifically to tumor necrosis factor alpha (TNF-alpha) and neutralizes its biological activity by blocking its interaction with the p55 and p75 cell surface TNF receptors. It also modulates biological responses induced or regulated by TNF, including changes in adhesion molecules and apoptosis.
SIMLANDI (adalimumab-adbm) is a tumor necrosis factor (TNF) blocker. It binds to TNF-alpha and inhibits its interaction with the p55 and p75 cell surface TNF receptors, thereby reducing inflammatory responses.
40 mg subcutaneously every 2 weeks; may increase to 40 mg weekly if inadequate response.
Subcutaneous injection, 40 mg every 2 weeks; may increase to 40 mg weekly if no response within 4 weeks.
None Documented
None Documented
Terminal elimination half-life approximately 2 weeks (12-16 days); supports every-2-week dosing in maintenance therapy.
Terminal elimination half-life is approximately 14 days (range 10–20 days) in patients with rheumatoid arthritis; this supports a subcutaneous dosing interval of every other week.
Renal: 0.1-0.5% as unchanged drug in urine; biliary/fecal: 70-90% as metabolites; mostly via reticuloendothelial system degradation.
Adalimumab is eliminated primarily via catabolism to small peptides and amino acids; renal excretion of intact drug is negligible (<1%). Biliary/fecal excretion of intact drug is minimal.
Category C
Category C
TNF-alpha Inhibitor
TNF-alpha Inhibitor